書誌事項
- タイトル別名
-
- Comparison of Sorafenib response evaluation with RECIST, mRECIST and RECICL for hepatocellular carcinoma
- カン サイボウガン ノ ソラフェニブ チリョウ コウカ ハンテイ ニ オケル RECIST modified RECIST RECICL キジュン ノ ヒカク
この論文をさがす
説明
RECIST, mRECIST and RECICL are criteria for evaluating the therapeutic response of hepatocellular carcinoma and there are several differences among these criteria. We investigated and compared differences in the response evaluation of sorafenib treatment. As a result, mRECIST and RECIST showed a 59% disease control rate, while RECICL and mRECIST showed an 11% response rate. In RECIST and mRECIST, CR/PR/SD groups demonstrated a significantly better prognosis (P=0.02) than PD. The SD group prognosis was significantly better (P=0.045) than that of the PD group in mRECIST. Multivariate analysis of factors contributing to survival yielded the following values: disease control of mRECIST or RECIST (P=0.005), Vp (P=0.008) and pre-treatment DCP (P=0.047). Concerning Sorafenib therapy, mRECIST tend to stratify the prognosis and was considered the most useful criteria at this time.<br>
収録刊行物
-
- 肝臓
-
肝臓 52 (5), 322-324, 2011
一般社団法人 日本肝臓学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679770454528
-
- NII論文ID
- 10029285474
- 10031039191
-
- NII書誌ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL書誌ID
- 11087530
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可